In the November/December 2015 issue of PharmaVOICE, Jeff Aroy comments on how the application of sensors, connectivity, and continuous monitoring can revolutionize drug development in some areas. To read the article, click here.
Low-priced oncology disruptors: The cuckoo in the PD-1/PD-L1 nest or the runt of the clutch?
Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant...